UBT is proud to share with all of you a big announcement:
the proposal MammoScreen, which we submitted in the context of the call HORIZON-MISS-2021-CANCER-02-01 “Develop new methods and technologies for cancer screening and early detection” has been selected for funding, with the total score of 15/15.
One of the goals of the call is to “update and expand screening and early detection programmes in EU”.
EU Missions are a novelty of the Horizon Europe research and innovation programme with the aim to bring concrete solutions to some of our greatest challenges and to improve the lives of millions of people
UBT Srl has participated in this highly competitive call within a Consortium constituted by:
Fondazione Toscana Life Sciences London South Bank University ELAROS 24/7 Limited SESCAM Scuola IMT Alti Studi Lucca EVITA – Cancro Hereditário
After the evaluation process, HORIZON Commission has decided to support our project MammoScreen.
This project represents a key milestone for UBT: it will give us the possibility of performing MammoWave clinical validation on thousands of participants and to address all the activities required to expand breast screening with MammoWave.
MammoWave aims to become the solution for a more inclusive breast cancer screening, assisting in reducing the risk of missing lesions: it can be used in all the asymptomatic population without any safety restrictions (such as age and frequency of use).
It can safely expand screening programs to women in the 20-49 and over 70 age ranges (this means additional 98 million women in EU)
Many thanks to the entire team and to all the partners we will be delighted to work with during the coming 48 months
